INS and metabolic dysfunction-associated steatotic liver disease: Current NAFLD drug developmental effort centers on repurposing fibric acid derivatives, which are lipid-lowering PPARα agonists and insulin sensitivity–improving PPARγ agonists, thiazolidinediones, but the clinical trials yielded mixed results [3, 4].